medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2014, Número 4

<< Anterior Siguiente >>

Rev Invest Clin 2014; 66 (4)


Factores celulares que restringen la replicación del virus de la inmunodeficiencia humana (VIH): nuevas esperanzas en la terapia antirretroviral

Moreno-Valencia Y, Álvarez-García LX, Vázquez-Pérez JA

Idioma: Español
Referencias bibliográficas: 58
Paginas: 359-368
Archivo PDF: 259.71 Kb.


RESUMEN

Para una replicación viral exitosa el virus de la inmunodeficiencia humana (VIH) se necesita en su célula blanco receptores y factores celulares del hospedero. En contraparte, el hospedero expresa diversas proteínas para contrarrestar la infección viral, tal es el caso de TRIM5a, Teterina o BST-2 y la familia de deaminasas de citidina APOBEC3. Estas proteínas, denominadas factores de restricción, forman parte de la respuesta inmune innata para el establecimiento de una línea de defensa temprana contra la infección. El factor celular mejor caracterizado es la proteína APOBEC3G, la cual ha demostrado tener un papel importante en la patogénesis del VIH. Es por eso que la caracterización y elucidación de cada uno de estos factores ofrecen un novedoso panorama para la investigación de nuevos elementos para una terapia antirretroviral.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Publicaciones de ONUSIDA - 2012 - Informe mundial: informe de ONUSIDA sobre la epidemia mundial de SIDA 2012. Disponible en: http://www.unaids.org/es/resources/publications/ 2012/name,76121,es.asp

  2. Barré-Sinoussi F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-71.

  3. Shaw GM, et al. Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science 1984; 226: 1165-71.

  4. Dalgleish AG, et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312: 763-7.

  5. Nakashima H, et al. Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy- associated virus by 3’-azido-3’-deoxythymidine in vitro. Antimicrob. Agents Chemother 1986; 30: 933-7.

  6. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246: 1155-8.

  7. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2012; 2, a007161.

  8. Gakhar H, Kamali A, Holodniy M. Health-related quality of life assessment after antiretroviral therapy: a review of the literature. Drugs 2013; 73: 651-72.

  9. Santoro MM, Perno CF. HIV-1 Genetic Variability and Clinical Implications. ISRN Microbiol 2013; 2013: 481314.

  10. Benjamin LA, et al. HIV infection and stroke: current perspectives and future directions. Lancet Neurol 2012; 11: 878-90.

  11. Stephenson KE, Barouch DH. A global approach to HIV-1 vaccine development. Immunol Rev 2013; 254: 295-304.

  12. Rerks-Ngarm S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-20.

  13. Malim MH, Bieniasz PD. HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harbor Perspectives in Medicine 2012; 2: a006940-a006940.

  14. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646-50.

  15. Goila-Gaur R, Strebel K. HIV-1 Vif, APOBEC, and Intrinsic Immunity. Retrovirology 2008; 5: 51.

  16. Lever RA, Lever AM. L. Intracellular defenses against HIV, viral evasion and novel therapeutic approaches. J Formos Med Assoc 2011; 110: 350-62.

  17. Strebel K, Luban J, Jeang K-T. Human cellular restriction factors that target HIV-1 replication. BMC Med 2009; 7: 48.

  18. Chang MO, Suzuki T, Yamamoto N, Watanabe M, Takaku H. HIV-1 Gag-Virus-Like Particles Inhibit HIV-1 Replication in Dendritic Cells and T Cells through IFN-a-Dependent Upregulation of APOBEC3G and 3F. J Innate Immunity 2012; 4: 579- 90.

  19. Chester A, Scott J, Anant S, Navaratnam N. RNA editing: cytidine to uridine conversion in apolipoprotein B mRNA. Biochim Biophys Acta 2000; 1494: 1-13.

  20. Muramatsu M. et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem 1999; 274: 18470-6.

  21. Liao W, et al. APOBEC-2, a cardiac- and skeletal muscle-specific member of the cytidine deaminase supergene family. Biochem Biophys Res Commun 1999; 260: 398-404.

  22. Bishop KN, Verma M, Kim E-Y, Wolinsky SM, Malim MH. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 2008; 4: e1000231.

  23. Vieira VC, Soares MA. The role of cytidine deaminases on innate immune responses against human viral infections. Biomed Res Int 2013; 683095 (2013).

  24. Holden LG, et al. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 2008; 456: 121-4.

  25. Chiu Y-L, et al. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2005; 435: 108-14.

  26. Hultquist JF, et al. Human and Rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H Demonstrate a Conserved Capacity To Restrict Vif-Deficient HIV-1. J Virology 2011; 85: 11220-34.

  27. Yu Q, et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 2004; 11: 435-42.

  28. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003; 9: 1404-07.

  29. Guo F, et al. The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J Virol 2007; 81: 11322-31.

  30. Santiago ML, et al. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 2008; 321; 1343-6.

  31. Münk C, Willemsen A, Bravo IG. An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol Biol 2012; 12: 71.

  32. Jónsson SR, et al. Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res 2006; 34: 5683-94.

  33. Huthoff H, Malim MH. Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins. Virology 2005; 334: 147-53.

  34. Russell RA, Pathak VK. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 2007; 81: 8201-10.

  35. Chen K, et al. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol 2006; 80: 7645-57.

  36. Biasin M, et al. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis 2007; 195: 960-4.

  37. Stopak KS, Chiu Y-L, Kropp J, Grant RM, Greene WC. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem 2007; 282: 3539-46.

  38. Vazquez-Perez JA. International AIDS Society - Poster Exhibition. Disponible en: http://www iasociety.org/ Default.aspx?pageId=735

  39. Valcke HS, et al. APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. AIDS 2006; 20, 1984-6.

  40. An P, et al. APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol 2004; 78: 11070-6.

  41. Do H. et al. Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. J Infect Dis 2005; 191: 159-63.

  42. Jin X, et al. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J Virol 2005; 79: 11513-6.

  43. Cho S-J, et al. APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. J Virol 2006; 80: 2069-72.

  44. Biasin M, et al. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis 2007; 195: 960-4.

  45. Vázquez-Pérez JA, Ormsby CE, Hernández-Juan R, Torres KJ, Reyes-Terán G. APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression. Retrovirology 2009; 6: 23.

  46. Jin X, et al. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J Virol 2005; 79: 11513-6.

  47. Farrow MA, et al. Nuclear localization of HIV type 1 Vif isolated from a long-term asymptomatic individual and potential role in virus attenuation. AIDS Res Hum Retroviruses 2005; 21: 565-74.

  48. Wang B, et al. First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection. Virology 2003; 312: 135-50.

  49. Newman RM, et al. Evolution of a TRIM5-CypA splice isoform in old world monkeys. PLoS Pathog 2008; 4: e1000003.

  50. Malim MH, Bieniasz PD. HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harb Perspect Med 2012; 2: a006940.

  51. Huthoff H, Towers GJ. Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha. Trends Microbiol 2008; 16: 612-9.

  52. Newman RM, Johnson WE. A brief history of TRIM5alpha. AIDS Rev 2007; 9: 114-25.

  53. Neil SJD, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451: 425-30.

  54. Mangeat B, et al. HIV-1 Vpu neutralizes the antiviral factor Tetherin/ BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 2009; 5: e1000574.

  55. Ali A, et al. Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication. Chem Med Chem 2012; 7, 1217-29.

  56. Laguette N, et al. SAMHD1 is the dendritic- and myeloid-cellspecific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474: 654-7.

  57. Rice GI, et al. Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 2009; 41: 829-32.

  58. Hultquist JF, et al. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol 2011; 85: 11220-34.




2020     |     www.medigraphic.com